(Q42848480)

8 November 2017

title

Oncogenic RAF: a brief history of time (English)

1 reference

8 November 2017

David Solit

1

1 reference

8 November 2017

Neal Rosen

series ordinal

2

1 reference

8 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20973931

9 August 2024

publication date

1 December 2010

1 reference

full work available at URL

8 November 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1755-148X.2010.00779.x

1 reference

10.1111/J.1755-148X.2010.00779.X

DOI

https://api.crossref.org/works/10.1111/J.1755-148X.2010.00779.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1755-148X.2010.00779.x

9 August 2024

1 reference

10.1111/J.1755-148X.2010.00779.X

DOI

https://api.crossref.org/works/10.1111/J.1755-148X.2010.00779.X

Pigment Cell & Melanoma Research

9 August 2024

published in

1 reference

8 November 2017

volume

23

1 reference

8 November 2017

issue

6

1 reference

8 November 2017

page(s)

760-762

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-148X.2010.00779.X

10.1111/J.1755-148X.2010.00779.X

21 January 2018

Identifiers

DOI

1 reference

8 November 2017

1 reference